Linganisha mbinu
Pitia mbinu ulizochagua bega kwa bega; safu zinazotofautiana zinaangaziwa.
| Utafiti wa Adaptive Diagnostic Accuracy× | Tathmini ya Kipimo cha Kuchuja× | |
|---|---|---|
| Nyanja | Epidemiolojia | Epidemiolojia |
| Familia | Process / pipeline | Process / pipeline |
| Mwaka wa asili≠ | 2000s–2010s (adaptive designs codified for diagnostics ~2010s) | 1968 (Wilson-Jungner principles); statistical framework developed 1970s–2000s |
| Mwanzilishi≠ | Adaptation of STARD framework (Bossuyt et al.) combined with adaptive design principles (Jennison & Turnbull; FDA guidance) | Wilson & Jungner (WHO criteria, 1968); foundational work by Pepe, Altman, and others in statistical test evaluation |
| Aina≠ | Adaptive observational/experimental study design | Observational diagnostic / epidemiological evaluation design |
| Chanzo asilia≠ | Bossuyt, P. M., Reitsma, J. B., Bruns, D. E., Gatsonis, C. A., Glasziou, P. P., Irwig, L., ... & Cohen, J. F. (2015). STARD 2015: an updated list of essential items for reporting diagnostic accuracy studies. BMJ, 351, h5527. DOI ↗ | Wilson, J. M. G., & Jungner, G. (1968). Principles and Practice of Screening for Disease. World Health Organization. Public Health Papers No. 34. link ↗ |
| Majina mbadala | adaptive DTA study, adaptive diagnostic test evaluation, adaptive test accuracy trial, adaptive STARD study | screening study, screening performance evaluation, screening accuracy assessment, STE |
| Zinazohusiana | 6 | 6 |
| Muhtasari≠ | An adaptive diagnostic accuracy study evaluates how well an index test distinguishes between patients with and without a target condition, while incorporating pre-specified interim analyses that allow modifications — such as sample size re-estimation, threshold adjustment, or subgroup enrichment — based on accumulating data. This design improves efficiency and ethical conduct compared to fixed-sample diagnostic studies, particularly when prior prevalence or test performance data are uncertain. | Screening test evaluation is a systematic epidemiological approach for assessing whether a test or program can accurately and cost-effectively identify individuals with a condition before symptoms appear. It quantifies diagnostic performance metrics — sensitivity, specificity, predictive values, and the ROC curve — and evaluates whether a screening program meets established public health criteria for adoption and harm-benefit balance. |
| ScholarGateSeti ya data ↗ |
|
|